The analgesic effectiveness of a narcotic agonist-antagonist analgesic is significantly potentiated by administering a narcotic agonist-antagonist analgesic together with at least one nontoxic NMDA recept or antagonist. The narcotic agonist-antagonist analgesic is selected from the group consisting of pentazocine nalbuphine butorphanol buprenorphine meptazinol dezocine nalorphine cyclazocine and pharmaceutically acceptable salts thereof. The nontoxic NMDA receptor antagonist is at least one memb...

Disclosed is a composition for delivery of a therapeutic compound comprising a condensation aerosol formed by volatilising a therapeutic compound selected from the group consisting of naltrexone buprenorphine naloxone butorphanol hyrdromorphone oxycodone methadone remifentanil or sufentanil under conditions effective to produce a heated vapour of the compound and condensing the heated vapour of the compound to form condensation aerosol particles; wherein said condensation aerosol particles are c...

Methods and compositions for treating managing or ameliorating pain in a subject (preferably a mammal and more preferably a human) comprising administration of a centrally acting (i.e. crosses the blood brain barrier) agonist of a k-opioid receptor and a centrally acting opioid antagonist such that the analgesia achieved by this administration is greater than with administration of either the k-opioid receptor agonist or the opioid antagonist alone. Preferably the -opioid receptor is nalbuphine ...

Methods and compositions for treating managing or ameliorating pain in a subject (preferably a mammal and more preferably a human) comprising administration of a centrally acting (i.e. crosses the blood brain barrier) agonist of a -opioid receptor and a centrally acting opioid antagonist such that the analgesia achieved by this administration is greater than with administration of either the -opioid receptor agonist or the opioid antagonist alone. Preferably the -opioid receptor is nalbuphine or...

1. An oral dosage form comprising (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is substantially not released when the dosage form is administered intact such that the ratio of the amount of antagonist released from said dosage form after tampering to the amount of said antagonist released from said intact dosage form is about 4:1 or greater based on the in-vitro dissolution at 1 hour of said dosage form in 900 ml of Simulated Gastric Fluid using a USP T...

A composition comprising the tannate of an opioid. Suitable opioids include alfentanil buprenorphine butorphanol carfentanil cocaine codeine dezocine diacetylmorphine dihydrocodeine dihydromorphine diphenoxylate diprenorphine etorphine fentanyl heroin hydrocodone hydromorphone -hydroxy-3-methylfentanyl levo--acetylmethadol levorphanol lofentanil meperidine methadone morphine nalbuphine nalmefene o-methylnaltrexone naloxone naltrexone oxycodone oxymorphone pentazocine pethidine propoxyphene remif...

Methods and compositions for treating managing or ameliorating pain in a subject (preferably a mammal and more preferably a human) comprising administration of a centrally acting (i.e. crosses the blood brain barrier) agonist of a k-opioid receptor and a centrally acting opioid antagonist such that the analgesia achieved by this administration is greater than with administration of either the k-opioid receptor agonist or the opioid antagonist alone. Preferably the -opioid receptor is nalbuphine ...

The invention relates to pharmaceutical drug compositions and preparations that are narcotic antagonists and analgesics specifically opioids more specifically morphine and its pharmaceutically active derivatives analogues homologues and metabolites and still more specifically hydromorphone and butorphanol. This invention also relates to pharmaceutical drug delivery devices specifically to devices for the intranasal administration of drugs classified as controlled substances. The invention also r...

The analgesic effectiveness of a narcotic agonist-antagonist analgesic is significantly potentiated by administering a narcotic agonist-antagonist analgesic together with at least one nontoxic NMDA receptor antagonist. The narcotic agonist-antagonist analgesic is selected from the group consisting of pentazocine nalbuphine butorphanol buprenorphine meptazinol dezocine nalorphine cyclazocine and pharmaceutically acceptable salts thereof. The nontoxic NMDA receptor antagonist is at least one membe...

1. A composition for treating pain comprising olanzapine or a pharmaceutically acceptable salt or solvate thereof; and one or more drug useful in the treatment of pain in a weight ratio of from about one part olanzapine to from about one (1) part to about one thousand (1000) parts drug useful in the treatment of pain. 2. A composition of claim 1 wherein the drug useful in the treatment of pain is an NSAIDS. 3. A composition of claim 2 wherein the NSAIDS is selected from the group consisting of a...